Palisade Bio presented at IBD Innovate: Product Development for Crohn’s & Colitis held April 9-10, 2024 in Cambridge, MA. As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company’s research partner, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio gave an oral presentation titled, “Advancing PALI-2108: Discovery to Strategy Positioning,” which discussed the development of PALI-2108, its differentiation and positioning in the competitive landscape as well as a clinical pathway towards late-stage development. “We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108. We continue to generate a growing body of data from PALI-2108 for the treatment of UC and remain on track to launch our Phase 1 clinical study later this year,” commented Dr. Jones. As previously announced, the development of PALI-2108 is supported by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio Inc trading halted, news pending
- Palisade Bio Announces 1-for-15 Reverse Stock Split
- Palisade Bio announces 1-for-15 reverse stock split
- Palisade Bio files to sell 3.63M shares of common stock for holders
- Palisade Bio, Inc.’s Success on the Line: The Critical Role of Retaining Top Talent Without Safeguards